SpyGlass Pharma reported a net loss of $19.9 million, or ($0.59) per share, for the quarter ended June 30, 2026, compared to an $8.7 million loss in the prior year period. Cash and short-term investments totaled $234.2 million as of June 30, 2026, which management expects will fund operations through 2028. The company announced that enrollment in its Phase 3 trials for the Bimatoprost Drug Pad-IOL System is on track for completion in 2027, while a first-in-human trial for the BIM-DRS is expected to begin in the second half of 2026. Additionally, SpyGlass appointed Mike Pinder as Vice President of Marketing and secured a new Category III CPT code (+1090T) to support reimbursement for its lead product candidate. SpyGlass Pharma operates in the biopharmaceutical industry, developing drug delivery solutions for glaucoma and ocular hypertension.